{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Andrew", "organization": "", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Insulin developer MannKind announces that Sanofi is ending agreement in which it had rights to market inhaled insulin called Afrezza; drug has not met sales expectations since Food and Drug Administration approval.", "multimedia": [{"type": "image", "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "legacy": {"wide": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "legacy": {"xlarge": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out", "main": "Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"}, "print_page": "2", "keywords": [{"value": "Sanofi SA", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "MannKind Corporation", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Mann, Alfred E", "is_major": "N", "rank": "3", "name": "persons"}, {"value": "Pfizer Inc", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Food and Drug Administration", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Diabetes", "is_major": "N", "rank": "6", "name": "subject"}], "snippet": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "source": "The New York Times", "lead_paragraph": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "word_count": "914", "pub_date": "2016-01-06T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html", "_id": "568c05fb38f0d803f4a0c464"}